James G Taylor Vi

List of Publications by Year
in descending order

88 papers	4,337 citations	87886 38 h-index	110368 64 g-index
89 all docs	89 docs citations	89 times ranked	5528 citing authors

#	Article	IF	Citations
1	Genetic determinants of telomere length from 109,122 ancestrally diverse whole-genome sequences in TOPMed. Cell Genomics, 2022, 2, 100084.	6.5	29
2	Urinary Kringle Domain-Containing Protein HGFL: A Validated Biomarker of Early Sickle Cell Anemia-Associated Kidney Disease. American Journal of Nephrology, 2021, 52, 582-587.	3.1	4
3	The gut microbiome in sickle cell disease: Characterization and potential implications. PLoS ONE, 2021, 16, e0255956.	2.5	24
4	Restriction of HIV-1 Infection in Sickle Cell Trait. Blood Advances, 2021, 5, 4922-4934.	5.2	2
5	Elevated Plasma Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) in Sickle Cell Disease - a Marker of Chronic Kidney Disease. Blood, 2021, 138, 968-968.	1.4	0
6	Influence of single parenthood on cardiopulmonary function in pediatric patients with sickle cell anemia. Blood Advances, 2020, 4, 3311-3314.	5.2	1
7	Association between plasma and urinary orosomucoid and chronic kidney disease in adults with sickle cell disease. British Journal of Haematology, 2020, 190, e45-e48.	2.5	8
8	Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The <scp>PUSH</scp> study. American Journal of Hematology, 2020, 95, 766-774.	4.1	19
9	Genome Wide Association Analysis of Iron Overload in the Trans-Omics for Precision Medicine (TOPMed) Sickle Cell Disease Cohorts. Blood, 2020, 136, 52-52.	1.4	1
10	Prevalence of Sickle Cell Trait and Rare Hemoglobin Variants in the Metropolitan Washington DC Area. Journal of Hematology (Brossard, Quebec), 2020, 9, 93-95.	1.0	3
11	Single Nucleotide Polymorphisms in SAR1A Codon Regions Associated with Hydroxyurea Response in Sickle Cell Disease and Potentially Influenced in Mirnas Binding. Blood, 2019, 134, 987-987.	1.4	0
12	Establishing a national sickle cell disease program in the Republic of Congo. Blood Advances, 2018, 2, 17-18.	5.2	2
13	Prostacyclin-analog therapy in sickle cell pulmonary hypertension. Haematologica, 2017, 102, e163-e165.	3.5	15
14	Central sensitization associated with low fetal hemoglobin levels in adults with sickle cell anemia. Scandinavian Journal of Pain, 2017, 17, 279-286.	1.3	18
15	A Locus on Chromosome 5 Is Associated with Red Cell Allo-Immunization in Adults with Sickle Cell Disease. Blood, 2017, 130, 956-956.	1.4	0
16	Transcriptional comparison of human induced and primary midbrain dopaminergic neurons. Scientific Reports, 2016, 6, 20270.	3.3	38
17	Memory Stem T Cells in Autoimmune Disease: High Frequency of Circulating CD8+ Memory Stem Cells in Acquired Aplastic Anemia. Journal of Immunology, 2016, 196, 1568-1578.	0.8	74
18	Liver injury is associated with mortality in sickle cell disease. Alimentary Pharmacology and Therapeutics, 2015, 42, 912-921.	3.7	44

#	Article	IF	Citations
19	Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia. PLoS ONE, 2015, 10, e0141706.	2.5	43
20	Identification of novel microRNA signatures linked to acquired aplastic anemia. Haematologica, 2015, 100, 1534-1545.	3.5	29
21	Epidermal devices for noninvasive, precise, and continuous mapping of macrovascular and microvascular blood flow. Science Advances, 2015, 1, e1500701.	10.3	189
22	Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide. British Journal of Haematology, 2015, 168, 737-746.	2.5	6
23	Frequency of Hospitalizations for Pain and Association With Altered Brain Network Connectivity in Sickle Cell Disease. Journal of Pain, 2015, 16, 1077-1086.	1.4	71
24	Iron, Inflammation, and Early Death in Adults With Sickle Cell Disease. Circulation Research, 2015, 116, 298-306.	4.5	71
25	High Frequency of Circulating CD8+ Memory Stem T Cells in Acquired Aplastic Anemia. Blood, 2015, 126, 3613-3613.	1.4	0
26	Sleep disturbance, depression and pain in adults with sickle cell disease. BMC Psychiatry, 2014, 14, 207.	2.6	78
27	A GCH1 haplotype confers sexâ€specific susceptibility to pain crises and altered endothelial function in adults with sickle cell anemia. American Journal of Hematology, 2014, 89, 187-193.	4.1	38
28	Alphaâ€thalassaemia and response to hydroxyurea in sickle cell anaemia. European Journal of Haematology, 2014, 92, 341-345.	2.2	14
29	Prediction of Fetal Hemoglobin in Sickle Cell Anemia Using an Ensemble of Genetic Risk Prediction Models. Circulation: Cardiovascular Genetics, 2014, 7, 110-115.	5.1	27
30	Heme-bound iron activates placenta growth factor in erythroid cells via erythroid KrÃ¼ppel-like factor. Blood, 2014, 124, 946-954.	1.4	40
31	Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom. PLoS ONE, 2014, 9, e99489.	2.5	107
32	Sequencing PCR-Amplified DNA in Lipoprotein and Cardiovascular Disease Research. Methods in Molecular Biology, 2013, 1027, 139-155.	0.9	0
33	Introduction to Next-Generation Nucleic Acid Sequencing in Cardiovascular Disease Research. Methods in Molecular Biology, 2013, 1027, 157-179.	0.9	1
34	Harnessing genomics to identify environmental determinants of heritable disease. Mutation Research - Reviews in Mutation Research, 2013, 752, 6-9.	5.5	25
35	Genetic determinants of haemolysis in sickle cell anaemia. British Journal of Haematology, 2013, 161, 270-278.	2.5	45
36	Hemodynamic Predictors of Mortality in Adults with Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 840-847.	5.6	114

#	Article	IF	Citations
37	Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin. Haematologica, 2013, 98, 455-463.	3.5	26
38	Case Series: Biliary Leak After Transjugular Liver Biopsy. American Journal of Gastroenterology, 2013, 108, 145-147.	0.4	6
39	Phase 1 Clinical Trial Of The Candidate Anti-Sickling Agent Aes-103 In Adults With Sickle Cell Anemia. Blood, 2013, 122, 1009-1009.	1.4	18
40	Severe Painful Vaso-Occlusive Crises and Mortality in a Contemporary Adult Sickle Cell Anemia Cohort Study. PLoS ONE, 2013, 8, e79923.	2.5	91
41	Therapeutic Hydroxyurea Dosing Is Associated With Decreased Organ Damage and Longer Survival In Adults With Sickle Cell Anemia. Blood, 2013, 122, 2228-2228.	1.4	0
42	Placenta Growth Factor Is Regulated By Heme-Bound Iron Via Erythroid KrÃ¼ppel-Like Factor In Erythroid Cells and Is Linked To Iron Status In Vivo In Sickle Cell Disease and Hereditary Hemochromatosis. Blood, 2013, 122, 432-432.	1.4	0
43	Admixture In Sickle Cell Disease Defined By Genome Wide Ancestry Informative Markers Varies By Geographic Region In The United States. Blood, 2013, 122, 995-995.	1.4	0
44	Reconstruction of thermographic signals to map perforator vessels in humans. Quantitative InfraRed Thermography Journal, 2012, 9, 123-133.	4.2	14
45	Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. Blood, 2012, 120, 1961-1962.	1.4	73
46	Markers of Severe Vaso-Occlusive Painful Episode Frequency in Children and Adolescents with Sickle Cell Anemia. Journal of Pediatrics, 2012, 160, 286-290.	1.8	84
47	Ancestry of African Americans with sickle cell disease. Blood Cells, Molecules, and Diseases, 2011, 47, 41-45.	1.4	35
48	Therapy-Related Acute Myelogenous Leukemia in a Hydroxyurea-Treated Patient With Sickle Cell Anemia. Annals of Internal Medicine, 2011, 155, 722.	3.9	13
49	Laboratory and echocardiography markers in sickle cell patients with leg ulcers. American Journal of Hematology, 2011, 86, 705-708.	4.1	42
50	Transcriptome profiling and sequencing of differentiated human hematopoietic stem cells reveal lineage-specific expression and alternative splicing of genes. Physiological Genomics, 2011, 43, 1117-1134.	2.3	13
51	Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom. Circulation, 2011, 124, 1452-1460.	1.6	124
52	Pleiotropic effects of intravascular haemolysis on vascular homeostasis. British Journal of Haematology, 2010, 148, 690-701.	2.5	62
53	Lipid levels in sickleâ€cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertension. British Journal of Haematology, 2010, 149, 436-445.	2.5	70
54	Hematologic, biochemical, and cardiopulmonary effects of <scp>l</scp>â€arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. European Journal of Haematology, 2009, 82, 315-321.	2.2	58

#	Article	IF	Citations
55	Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. American Journal of Hematology, 2009, 84, 529-531.	4.1	37
56	Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. British Journal of Haematology, 2009, 145, 506-513.	2.5	85
57	Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. Journal of Clinical Investigation, 2009, 119, 3395-407.	8.2	237
58	A GCH1 Haplotype Associated with Susceptibility to Vasoocclusive Pain and Impaired Vascular Function in Sickle Cell Anemia.. Blood, 2009, 114, 575-575.	1.4	5
59	Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. American Journal of Hematology, 2008, 83, 15-18.	4.1	108
60	Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. American Journal of Hematology, 2008, 83, 6-14.	4.1	60
61	Severe pulmonary hypertension in an adolescent with sickle cell disease. American Journal of Hematology, 2008, 83, 71-72.	4.1	5
62	Sickle cell disease and pulmonary hypertension in Africa: A global perspective and review of epidemiology, pathophysiology, and management. American Journal of Hematology, 2008, 83, 63-70.	4.1	91
63	Transplantâ€associated Ochroconis gallopava infections. Transplant Infectious Disease, 2008, 10, 442-448.	1.7	49
64	Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia. British Journal of Haematology, 2008, 141, 254-259.	2.5	49
65	Severe Vaso-Occlusive Episodes Associated with Use of Systemic Corticosteroids in Patients with Sickle Cell Disease. Journal of the National Medical Association, 2008, 100, 948-951.	0.8	69
66	Chronic Hyper-Hemolysis in Sickle Cell Anemia: Association of Vascular Complications and Mortality with Less Frequent Vasoocclusive Pain. PLoS ONE, 2008, 3, e2095.	2.5	152
67	A network model to predict the risk of death in sickle cell disease. Blood, 2007, 110, 2727-2735.	1.4	159
68	Functional profiling of uncommonVCAM1promoter polymorphisms prevalent in African American populations. Human Mutation, 2007, 28, 824-829.	2.5	15
69	Genomic and functional analysis of the sodium-dependent vitamin C transporter SLC23A1â€“SVCT1. Genes and Nutrition, 2007, 2, 143-145.	2.5	12
70	Variation in the Small Guanosine Triphosphate (GTP)-Binding Protein, Secretion-Associated and RAS-Related (SAR1A) Gene and Response to Hydroxyurea Treatment in Sickle Cell Disease.. Blood, 2007, 110, 3392-3392.	1.4	1
71	Phosphodiesterase Inhibition Increases Fetal Hemoglobin in Sickle Cell Disease; L-Arginine Supplementation Does Not.. Blood, 2007, 110, 3396-3396.	1.4	0
72	Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood, 2006, 107, 2279-2285.	1.4	561

#	Article	IF	Citations
73	Cerebrovascular disease associated with sickle cell pulmonary hypertension. American Journal of Hematology, 2006, 81, 503-510.	4.1	90
74	The Hyperhemolysis Phenotype in Sickle Cell Anemia: Increased Risk of Leg Ulcers, Priapism, Pulmonary Hypertension and Death with Decreased Risk of Vasoocclusive Events.. Blood, 2006, 108, 787-787.	1.4	4
75	vRare VCAM1 Promoter Haplotypes Prevalent in African Americans Are Hyperinducible.. Blood, 2006, 108, 1813-1813.	1.4	0
76	Mutations and Polymorphisms Influencing Hemolysis in Hemoglobin Genes and Risk of Pulmonary Hypertension in Sickle Cell Disease: Effect of Hemoglobin SC.. Blood, 2006, 108, 1206-1206.	1.4	0
77	Arginine Metabolite Profiling in Sickle Cell Disease: Abnormal Levels and Correlations with Pulmonary Hypertension, Desaturation, Hemolysis and Organ Dysfunction.. Blood, 2006, 108, 1205-1205.	1.4	0
78	Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica, 2006, 91, 1076-83.	3.5	45
79	Common polymorphisms in critical genes of innate immunity do not contribute to the risk for chronic disseminated candidiasis in adult leukemia patients. Medical Mycology, 2005, 43, 349-353.	0.7	21
80	Sequence analysis of the mannose-binding lectin (MBL2) gene reveals a high degree of heterozygosity with evidence of selection. Genes and Immunity, 2004, 5, 461-476.	4.1	79
81	Comparison of the genomic structure and variation in the two human sodium-dependent vitamin C transporters, SLC23A1 and SLC23A2. Human Genetics, 2004, 115, 285-94.	3.8	59
82	Association between Chronic Disseminated Candidiasis in Adult Acute Leukemia and CommonIL4Promoter Haplotypes. Journal of Infectious Diseases, 2003, 187, 1153-1156.	4.0	50
83	Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood, 2002, 100, 4303-4309.	1.4	97
84	Using genetic variation to study immunomodulation. Current Opinion in Pharmacology, 2002, 2, 463-469.	3.5	32
85	Patterns of low-affinity immunoglobulin receptor polymorphisms in stroke and homozygous sickle cell disease. American Journal of Hematology, 2002, 69, 109-114.	4.1	12
86	Using genetic variation to study human disease. Trends in Molecular Medicine, 2001, 7, 507-512.	6.7	128
87	Toward quantitative genetic analysis of host and parasite traits in the manifestations of Plasmodium falciparum malaria. Current Opinion in Genetics and Development, 2000, 10, 314-319.	3.3	7
88	Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S. Blood, 2000, 96, 2358-2363.	1.4	108